Afya Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AFYA research report →
Range $12.6 – $17
Price Chart
About the company
Afya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical schools, preparatory courses for medical residency, advanced graduate studies, and various other programs tailored for medical professionals at all career stages. These offerings are available across its proprietary network and are also extended to external medical institutions.
- CEO
- Virgilio Deloy Capobianco Gibbon
- IPO
- 2019
- Employees
- 9,395
- HQ
- Belo Horizonte, MG, BR
Get TickerSpark's AI analysis on AFYA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $871.54M
- P/E
- 6.44
- Fwd P/E
- 1.17
- PEG
- 0.57
- P/S
- 1.35
- P/B
- 1.00
- EV/EBITDA
- 4.41
- Div Yield
- 6.75%
- Gross Margin
- 63.81%
- Op Margin
- 32.35%
- Net Margin
- 20.39%
- ROE
- 16.36%
- ROIC
- 12.59%
Latest fiscal year · YoY change
- Revenue
- $3.62B+9.7%
- Gross Profit
- $2.34B+11.9%
- Op Income
- $1.19B
- Net Income
- $737.68M+16.8%
- EPS
- $8.16+16.4%
- OCF Growth
- -16.3%
- FCF Growth
- -0.3%
- 52W High
- $16.16
- 52W Low
- $9.52
- 50D MA
- $12.50
- 200D MA
- $13.89
- Beta
- 0.37
- RSI (14)
- 29
- Avg Volume
- 401.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Afya delivered mid-single-digit revenue growth, expanded margins, and strong cash generation, while signaling continued optimism in medical education and a more measured outlook for Continuing Education monetization.· November 12, 2026
- Q3 revenue rose 6% year over year to BRL 985 million, adjusted EBITDA rose 9% to BRL 434 million, and adjusted EBITDA margin improved to 44%.
- Nine-month revenue reached BRL 2,970 million, adjusted EBITDA was BRL 1.3 billion, and net income was BRL 634 million; basic EPS reached BRL 6.98, up 9%.
- Cash generation remained strong with 99.5% cash conversion and BRL 629 million of free cash flow to equity in the first 9 months.
- Undergrad remained the core growth engine, with 3,785 operating medical seats, more than 26,000 medical students, and a 4% increase in medical school net average ticket to BRL 9,466.
- Management returned BRL 459 million to shareholders in 9M 2026 through dividends and buybacks, while net debt fell to BRL 1.2 billion and leverage was 0.7x EBITDA excluding IFRS 16.
- Continuing Education and Medical Practice Solutions grew more slowly as Afya invested to expand user bases, and management said monetization is being affected by mix shift toward shorter, lower-ticket offerings.
Third-quarter 2026 revenue was BRL 985 million, up 6% year over year. Adjusted EBITDA was BRL 434 million, up 9% year over year, and adjusted EBITDA margin was 44%, an expansion of 100 basis points. Net income in the quarter was BRL 171 million, up 7%, and EPS was BRL 1.88, up 10%. For the first 9 months of 2026, revenue reached BRL 2,970 million, adjusted EBITDA reached BRL 1.3 billion / BRL 1,352 million, net income was BRL 634 million, and basic EPS was BRL 6.98. Revenue grew 7% over 9M 2025, adjusted EBITDA grew 5%, and net income rose 7%. Cash flow from operating activities was BRL 1,333 million in 9M 2026, cash conversion was 99.5%, free cash flow to equity was BRL 629 million, and shareholder returns totaled BRL 459 million. Gross debt was BRL 2.5 billion, net debt was BRL 1.2 billion, average debt cost was 15.2% per year, and net debt excluding IFRS 16 was 0.7x the midpoint of 2026 adjusted EBITDA guidance. Management reiterated full-year 2026 guidance and said CapEx guidance remains BRL 340 million to BRL 380 million for the year. They also said 2027 guidance will be given with full-year 2026 results in March.
Virgilio Gibbon framed the quarter as evidence that Afya’s strategy is supporting sustainable growth and “transforming medical education across Brazil.” He emphasized leadership in medical education, 100% occupancy across medical programs, and expansion in health-science offerings, while highlighting the company’s AA MSCI ESG rating as a strategic milestone. His tone was upbeat but measured, especially on near-term intake timing and 2027 visibility.
Luis Andre Blanco focused on operational efficiency, margin expansion, and balance sheet discipline. He noted that the Q3 margin expansion was mainly driven by higher gross margins in Undergraduate, partly offset by margin pressure in Continuing Education and Medical Practice Solutions due to investment and higher sales and marketing spend. He also pointed to solid cash generation, BRL 1,333 million of operating cash flow in 9M 2026, BRL 629 million of free cash flow to equity, BRL 459 million returned to shareholders, and net debt of BRL 1.2 billion with a 0.7x leverage ratio excluding IFRS 16.
Analysts asked about the 2027 medical intake environment, ticket dynamics, gross margin expansion in Undergrad, ENAMED preparation, weak revenue monetization in Continuing Education, B2B trends, receivables and FIES, and CapEx. Management said it is too early to comment on 2027 intake, but ticket increases of 5.7% over gross tuition for next year are already in place and they sounded optimistic. On ENAMED, they said internal assessments suggest students performed about 18 percentage points above the prior exam on an average basis, with no extra ENAMED-related cost pressure because preparation is handled internally. They said Continuing Education is being driven by more short-duration, lower-ticket courses, which is slowing revenue per student, and they expect this mix issue to persist near term; on receivables, they cited a 64% increase in FIES versus December and said CapEx should still land within BRL 340 million to BRL 380 million.
The call showed Afya still growing in its core medical education business, with higher seats, more students, and better pricing in the undergraduate segment. Strong cash conversion, rising free cash flow, and continued shareholder returns support the view that the business can fund growth while maintaining a conservative balance sheet.
The slower growth in Continuing Education and Medical Practice Solutions suggests monetization is not keeping pace with user growth, and management expects this mix pressure to continue in the near term. Working capital is also under pressure from FIES receivables, and management acknowledged CapEx pacing has been below plan even though they still expect to hit the annual target.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 27.1%
- Shares Outstanding
- 91.45M
- Float Shares
- 24.78M
of shares held by institutions
55 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 2.96M | ▲ 342.40K |
| Softbank Group Corp. | 2.43M | 0 |
| Doma Perpetual Capital Management LLC | 2.40M | ▲ 115.74K |
| Bamco Inc | 1.18M | ▼ 307.41K |
| Renaissance Technologies LLC | 531.90K | ▲ 188.60K |
| Two Sigma Advisers, LP | 268.40K | ▼ 7.80K |
| Swedbank Ab | 189.20K | 0 |
| Two Sigma Investments, LP | 155.71K | ▼ 166.57K |
| Citadel Advisors LLC | 108.59K | ▲ 59.70K |
| D. E. Shaw & Co., Inc. | 107.28K | ▲ 2.78K |
| Qube Research & Technologies Ltd | 99.63K | ▲ 99.63K |
| Bank Of America Corp | 75.79K | ▼ 8.61K |
Held by 18 ETFs
Biggest fund positions in AFYA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 5, 26 | FERREIRA SANTOS WELDER | sell | 4,161 |
| Jul 1, 26 | Junior Lelio de Souza | sell | 36,204 |
| Jun 26, 26 | Basolli Gomiero Mirella | sell | 10,000 |
| Jun 26, 26 | Junior Lelio de Souza | sell | 41,541 |
| May 7, 26 | Gibbon Virgilio Deloy Capobianco | other | 59,000 |
| May 7, 26 | Gibbon Virgilio Deloy Capobianco | other | 16,225 |
| May 7, 26 | Gibbon Virgilio Deloy Capobianco | other | 9,000 |
| May 7, 26 | Gibbon Virgilio Deloy Capobianco | other | 32,000 |
| May 7, 26 | DEL BIANCO DENIS | other | 3,500 |
| May 7, 26 | DEL BIANCO DENIS | other | 21,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AFYA coverage
Recent articles, reports, and earnings notes.
No research on AFYA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AFYA report →10 Graham Value Dividend All-Stars (GVAS) Extol November
seekingalpha.com · Nov 17
Afya: The Drop Came From Brazil, Not From The Company (Buy Rating)
seekingalpha.com · Nov 13
Afya: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 13
Afya Limited (AFYA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
What Afya (AFYA) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Afya (AFYA) Q3 Earnings Lag Estimates
zacks.com · Nov 12
Afya Limited Announces Third Quarter and Nine Months 2026 Financial Results
businesswire.com · Nov 12
Afya (AFYA) Earnings Expected to Grow: Should You Buy?
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.